PM: DHL Group erwirbt CRYOPDP von Cryoport und stärkt damit „DHL Health Logistics“
PR: DHL Group acquires CRYOPDP from Cryoport to strengthen “DHL Health Logistics”
- Photo Info
- Download
- 3 additional media items
DHL Group erwirbt CRYOPDP von Cryoport und stärkt damit „DHL Health Logistics“
- DHL erwirbt 100 Prozent von CRYOPDP, einem führenden Anbieter spezialisierter Logistikservices für die Bereiche Klinische Versuche, Biopharma und Zell- und Gentherapie. Mit dieser Akquisition erweitert DHL seine Kompetenzen in der Spezialpharmalogistik und unterstützt die Strategie 2030 des Konzerns, sich als führendes Unternehmen im Bereich Life-Sciences- und Healthcare zu etablieren.
- DHL und Cryoport gehen eine strategische Partnerschaft ein. Damit wollen beide Unternehmen ihr Angebot an Supply-Chain-Services für den globalen Life-Sciences- und Healthcare-Sektor stärken.
DHL, BONN, und Cryoport, NASHVILLE, Tennessee, (31. März 2025) – DHL Group („DHL“), der weltweit führende Logistikanbieter, und Cryoport , Inc. (NASDAQ: CYRX) („Cryoport”), ein globaler Anbieter von Supply-Chain-Lösungen für den Life-Sciences-Sektor, geben bekannt, dass DHL 100 Prozent von CRYOPDP erworben hat. CRYOPDP ist Anbieter von Kurierdienstleistungen im Bereich Klinische Studien, Biopharma und Zell- und Gentherapien. Die beiden Unternehmen geben auch bekannt, dass sie eine strategische Partnerschaft eingegangen sind, um ihr Angebot an Supply-Chain-Services für den Life-Sciences- und Healthcare-Sektor zu stärken.
DHL Group verfügt bereits über ein etabliertes Life-Sciences- und Healthcare-Geschäft, das im Jahr 2024 über fünf Milliarden Euro zum weltweiten Umsatz beigetragen hat. Aufbauend auf dieser soliden Basis ist die Übernahme von CRYOPDP ein bedeutender Schritt, mit dem DHL seine Kompetenzen in der Spezialpharmalogistik optimieren und sein Angebot im schnell wachsenden Life-Sciences- und Healthcare-Sektor erweitern will. CRYOPDP hat sich auf diese sogenannten „White-Glove“-Kurierdienstleistungen spezialisiert, die für ihre Kunden enorm wichtig sind. Mit Niederlassungen in 15 Ländern bearbeitet CRYOPDP über 600.000 Sendungen pro Jahr und beliefert Kunden und Patienten in über 135 Ländern weltweit.
In Zukunft wird DHL Supply Chain die Expertise des neu erworbenen Spezialanbieters CRYOPDP sowie die globalen Luftfrachtleistungen von DHL Express und DHL Global Forwarding nutzen und damit sein Pharma Specialized Network ausbauen und das Potential noch maximieren.
Die strategische Partnerschaft mit Cryoport bringt die Fähigkeiten von DHL in der globalen Healthcare-Logistik mit der marktführenden Expertise von Cryoport in der Bereitstellung von Speziallösungen im diesem schnell wachsenden Markt zusammen. Außerdem stärkt sie die Beziehungen zwischen DHL und den übrigen Geschäftsbereichen von Cryoport im Bereich der spezialisierten Pharmaindustrie.
Oscar de Bok, CEO von DHL Supply Chain, sagte: „Die Übernahme von CRYOPDP ist ein entscheidender Schritt für unser Supply-Chain-Geschäft, da wir unser Pharma Specialized Network weiter ausbauen wollen, um den sich wandelnden Anforderungen des Bereichs Klinische Studien, Biopharma und Zell- und Gentherapien gerecht zu werden und gleichzeitig unsere Präsenz im konventionellen Pharma- und Life-Sciences-Healthcare-Segment weiter zu stärken. Die Übernahme von CRYOPDP und die erweiterte Partnerschaft mit Cryoport Inc. ermöglichen es uns, integrierte End-to-End-Lösungen anzubieten, die unsere Kapazitäten zu verbessern.“
Jerrell Shelton, CEO von Cryoport, sagte: „Wir freuen uns sehr, dass wir unsere vertrauensvolle Zusammenarbeit mit DHL Group weiter ausbauen können. Gemeinsam werden wir ein erweitertes Spektrum an Lieferkettenlösungen anbieten, um die kritischen Anforderungen von Unternehmen und Patienten an die Lieferkette zu erfüllen. Diese strategische Partnerschaft kombiniert die starke Expertise von DHL Supply Chain und CRYOPDP und bietet Cryoport die Möglichkeit, seine Präsenz in globalen Wachstumsmärkten wie dem Asiatisch-Pazifischen Raum, sowie Europa, dem Nahen Osten und Afrika weiter auszubauen.“
Die Übernahme fügt sich nahtlos in die Strategie 2030 von DHL Group ein. Diese legt einen Schwerpunkt auf temperaturgeführte Logistiknetzwerke, spezialisierte Kurierdienstleistungen für die erste und letzte Meile und integrierte Lösungen. Die Expertise von CRYOPDP wird maßgeblich dazu beitragen, diese Ziele zu verwirklichen und DHL als führenden Anbieter für die Pharmaindustrie zu positionieren. Von diesem strategischen Schritt sollen auch Kosteneinsparungen und eine Verbesserung des Servicelevels ausgehen. Insbesondere durch die Nutzung der Luftfrachtkapazitäten von DHL Express und DHL Global Forwarding wird sich DHL im anspruchsvollen Spezialpharmasektor weiter steigern.
Die Partnerschaft mit DHL ermöglicht es Cryoport umgekehrt, sein Geschäft in den Regionen EMEA und APAC mit verstärktem Fokus auf das eigen Kerngeschäft gezielter ausbauen. Dies eröffnet zusätzliche Möglichkeiten, erstklassige und maßgeschneiderte Services anzubieten, um die Marktnachfrage nach seinen Produkten und Services zu bedienen.
Das Geschäft und die Partnerschaft stehen unter Vorbehalt der behördlichen Genehmigungen.
– End –
DHL Contacts:
DHL Group
Media Relations
Daniel Pohl
Phone: +49 228 182-9944
E-mail: pressestelle@dhl.com
On the internet: group.dhl.com/press
Follow us at: twitter.com/DHLglobal
Cryoport Contacts:
Investor Contacts:
Todd Fromer / Scott Eckstein
KCSA Strategic Communications
Cryoport Media Contacts:
Caitlin Kasunich / Michaela Fawcett
KCSA Strategic Communications
DHL – The logistics company for the world
DHL is the leading global brand in the logistics industry. Our DHL divisions offer an unrivalled portfolio of logistics services ranging from national and international parcel delivery, e-commerce shipping and fulfillment solutions, international express, road, air and ocean transport to industrial supply chain management. With about 395,000 employees in more than 220 countries and territories worldwide, DHL connects people and businesses securely and reliably, enabling global sustainable trade flows. With specialized solutions for growth markets and industries including technology, life sciences and healthcare, engineering, manufacturing & energy, auto-mobility and retail, DHL is decisively positioned as “The logistics company for the world”.
DHL is part of DHL Group. The Group generated revenues of more than 81.8 billion euros in 2023. With sustainable business practices and a commitment to society and the environment, the Group makes a positive contribution to the world. DHL Group aims to achieve net-zero emissions logistics by 2050.
About Cryoport, Inc.
Cryoport, Inc. (Nasdaq: CYRX), is a global leader in supply chain solutions for the Life Sciences with an emphasis on cell & gene therapies. Cryoport enables manufacturers, contract manufacturers (CDMOs), contract research organizations (CROs), developers, and researchers to carry out their respective business with products and services that are designed to derisk services and provide certainty. We provide a broad array of supply chain solutions for the life sciences industry. Through our platform of critical products and solutions including advanced temperature-controlled packaging, informatics, specialized bio-logistics services, bio-storage, bio-services, and cryogenic systems, we are “Enabling the Future of Medicine™” worldwide, through our innovative systems, compliant procedures, and agile approach to superior supply chain management.
Our corporate headquarters, located in Nashville, Tennessee, is complemented by over 50 global locations in 17 countries, with key sites in the United States, United Kingdom, France, the Netherlands, Belgium, Portugal, Germany, Japan, Australia, India, and China.
For more information, visit www.cryoportinc.com or follow via LinkedIn at https://www.linkedin.com/company/cryoportinc or @cryoport on X, formerly known as Twitter at www.twitter.com/cryoport for live updates.
Forward-Looking Statements
Statements in this press release which are not purely historical, including statements regarding Cryoport’s intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, those related to Cryoport's expectations about future benefits of the sale of CRYOPDP and the strategic collaboration with DHL, including the potential impact on future revenue and revenue streams. It is important to note that Cryoport’s actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, risks and uncertainties associated with the effect of changing economic and geopolitical conditions, supply chain constraints, inflationary pressures, the effects of foreign currency fluctuations, trends in the products markets, variations in Cryoport’s cash flow, market acceptance risks, and technical development risks. Cryoport’s business could be affected by other factors discussed in Cryoport’s SEC reports, including in the “Risk Factors” section of its most recently filed periodic reports on Form 10-K and Form 10-Q, as well as in its subsequent filings with the SEC. The forward-looking statements contained in this press release speak only as of the date hereof and Cryoport cautions investors not to place undue reliance on these forward-looking statements. Except as required by law, Cryoport disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.
DHL Group acquires CRYOPDP from Cryoport to strengthen “DHL Health Logistics”
- DHL to acquire 100% of CRYOPDP, a leading specialty courier providing logistics services for clinical trials, biopharma, and cell & gene therapies. This acquisition enhances DHL’s capabilities in specialty pharma logistics and supports Group’s 2030 strategy to become a leader in life science and healthcare logistics.
- DHL and Cryoport form strategic partnership to strengthen their respective supply chain services offerings for the global life sciences and healthcare sector.
DHL, BONN, Germany and Cryoport, NASHVILLE, Tenn., (March 31, 2025) - DHL Group (“DHL”), the world's leading logistics provider, and Cryoport, Inc. (NASDAQ: CYRX) (“Cryoport”), a global provider of supply chain solutions for the life sciences sector, are pleased to announce that DHL has acquired 100% of CRYOPDP, a leading specialty courier focused on clinical trials, biopharma, and cell and gene therapies. In this context, the companies also announced a strategic partnership to strengthen their supply chain service offerings for the global life sciences and healthcare sector.
DHL Group already has an established Life Sciences and Healthcare business, contributing over EUR 5 billion in global revenue in 2024. Building on this foundation, the acquisition of CRYOPDP marks a significant step in DHL's commitment to enhancing its capabilities in specialized pharma logistics and expanding the breadth of its offering in the rapidly growing life science and healthcare sector. CRYOPDP specializes in providing white-glove courier services essential to the sectors it serves. With operations in 15 countries, CRYOPDP handles over 600,000 shipments per year, servicing customers and patients in over 135 countries worldwide.
Going forward, DHL Supply Chain will further build the potential of its Pharma Specialized Network solution by leveraging the specialty courier expertise of newly acquired CRYOPDP and the global air capabilities of DHL Express and DHL Global Forwarding.
The strategic partnership with Cryoport will bring together DHL’s global health logistics capabilities with Cryoport's industry-leading expertise in providing specialized solutions in a fast growing life science and healthcare market segment. It also deepens DHL’s relationship with all the Cryoport business units with respect to specialized pharma.
Oscar de Bok, CEO of DHL Supply Chain, stated, “The acquisition of CRYOPDP is a pivotal move for our supply chain business as we aim to expand our Pharma Specialized Network to meet the evolving needs of clinical trials, biopharma and cell & gene therapies, in addition to further increasing our footprint in the conventional pharma and life science healthcare segment. The acquisition of CRYOPDP and the extended partnership with Cryoport Inc. will enable us to deliver integrated end-to-end solutions, enhancing our service capabilities .”
Jerrell Shelton, CEO of Cryoport, commented “We are indeed pleased to build on our trusted relationship with the DHL Group. Working together we will bring an enhanced set of supply chain solutions to meet companies’ and patients’ critical supply chain needs. This strategic partnership taps into the strong expertise of DHL’s Supply Chain and CRYOPDP, presenting a substantial opportunity for Cryoport to further expand its reach to global growth markets such as Asia Pacific (APAC) and Europe, Middle East and Africa (EMEA).”
The acquisition aligns with DHL Group’s Strategy 2030, which emphasizes the importance of temperature-controlled networks, first and last mile specialty courier coverage and integrated solutions. CRYOPDP’s capabilities will be instrumental in achieving these objectives and help position DHL as a leader in providing comprehensive solutions for the pharma industry. This strategic move is also expected to yield cost savings and improve overall service levels, especially leveraging DHL Express and DHL Global Forwarding air capabilities, ultimately enhancing DHL’s footprint in the high-value advanced pharma sector.
For Cryoport, the partnership with DHL will enable it to better execute its business in EMEA and APAC with a stronger focus on its core business in these regions, creating even greater opportunities to offer highly targeted, top-tier services in answering market demand for its services and products.
The deal and the outlined partnership are subject to regulatory approvals.
– End –
DHL Contacts:
DHL Group
Media Relations
Daniel Pohl
Phone: +49 228 182-9944
E-mail: pressestelle@dhl.com
On the internet: group.dhl.com/press
Follow us at: twitter.com/DHLglobal
Cryoport Contacts:
Investor Contacts:
Todd Fromer / Scott Eckstein
KCSA Strategic Communications
Cryoport Media Contacts:
Caitlin Kasunich / Michaela Fawcett
KCSA Strategic Communications
DHL – The logistics company for the world
DHL is the leading global brand in the logistics industry. Our DHL divisions offer an unrivalled portfolio of logistics services ranging from national and international parcel delivery, e-commerce shipping and fulfillment solutions, international express, road, air and ocean transport to industrial supply chain management. With about 395,000 employees in more than 220 countries and territories worldwide, DHL connects people and businesses securely and reliably, enabling global sustainable trade flows. With specialized solutions for growth markets and industries including technology, life sciences and healthcare, engineering, manufacturing & energy, auto-mobility and retail, DHL is decisively positioned as “The logistics company for the world”.
DHL is part of DHL Group. The Group generated revenues of more than 81.8 billion euros in 2023. With sustainable business practices and a commitment to society and the environment, the Group makes a positive contribution to the world. DHL Group aims to achieve net-zero emissions logistics by 2050.
About Cryoport, Inc.
Cryoport, Inc. (Nasdaq: CYRX), is a global leader in supply chain solutions for the Life Sciences with an emphasis on cell & gene therapies. Cryoport enables manufacturers, contract manufacturers (CDMOs), contract research organizations (CROs), developers, and researchers to carry out their respective business with products and services that are designed to derisk services and provide certainty. We provide a broad array of supply chain solutions for the life sciences industry. Through our platform of critical products and solutions including advanced temperature-controlled packaging, informatics, specialized bio-logistics services, bio-storage, bio-services, and cryogenic systems, we are “Enabling the Future of Medicine™” worldwide, through our innovative systems, compliant procedures, and agile approach to superior supply chain management.
Our corporate headquarters, located in Nashville, Tennessee, is complemented by over 50 global locations in 17 countries, with key sites in the United States, United Kingdom, France, the Netherlands, Belgium, Portugal, Germany, Japan, Australia, India, and China.
For more information, visit www.cryoportinc.com or follow via LinkedIn at https://www.linkedin.com/company/cryoportinc or @cryoport on X, formerly known as Twitter at www.twitter.com/cryoport for live updates.
Forward-Looking Statements
Statements in this press release which are not purely historical, including statements regarding Cryoport’s intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, those related to Cryoport's expectations about future benefits of the sale of CRYOPDP and the strategic collaboration with DHL, including the potential impact on future revenue and revenue streams. It is important to note that Cryoport’s actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, risks and uncertainties associated with the effect of changing economic and geopolitical conditions, supply chain constraints, inflationary pressures, the effects of foreign currency fluctuations, trends in the products markets, variations in Cryoport’s cash flow, market acceptance risks, and technical development risks. Cryoport’s business could be affected by other factors discussed in Cryoport’s SEC reports, including in the “Risk Factors” section of its most recently filed periodic reports on Form 10-K and Form 10-Q, as well as in its subsequent filings with the SEC. The forward-looking statements contained in this press release speak only as of the date hereof and Cryoport cautions investors not to place undue reliance on these forward-looking statements. Except as required by law, Cryoport disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.
Mit freundlichen Grüßen / With kind regards
DHL Group
